Charles River Laboratories Intl. Inc vs Petróleo Brasileiro SA — how do they compare? Charles River Laboratories Intl. Inc trades at $303.91 (market cap $14.23B), while Petróleo Brasileiro SA trades at $25.27 (market cap $151.94B). The key difference: Petróleo Brasileiro SA is far larger — about 10.7× Charles River Laboratories Intl. Inc's market cap, and Petróleo Brasileiro SA pays a 6.79% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Petróleo Brasileiro SA for 25 Days on average.
| CRL | PBR | |
|---|---|---|
Market Cap | $14.23B | $151.94B |
Volume | 1,176,885 | 30,240,092 |
Sector | Health | Energy |
52-Week High | $310.77 | $24.69 |
52-Week Low | $149.93 | $11.54 |
Typical Hold Time | 33 Days | 25 Days |
Enterprise Value | $17.06B | $212.36B |
Dividend Yield | — | 6.79% |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Petrobras (PBR) is trading at $25.16, up 4.88% with strong bullish momentum. The stock shows robust fundamentals with a P/E of 6.24, net margin of 24.52%, and positive earnings surprises in recent quarters. Recent news highlights new oil discoveries and production growth initiatives, while technical indicators show overbought conditions with RSI above 80.
PBR offers attractive valuation metrics and strong profitability, but faces risks from political interference and commodity price volatility. Analyst consensus leans bullish with 50% buy ratings, though the current price exceeds the $22.33 consensus target. The company's expansion projects and LNG deals provide long-term growth catalysts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →